CHMP, Sarclisa and multiple myeloma
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
News Medical on MSN1d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...
clinicaltrialsarena on MSN11h
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback